1 Automated Derivation of Diagnostic Criteria for Lung Cancer using Natural Language Processing on
2 Electronic Health Records: A pilot study.

-
- 2 **Electronic Health Records: A pilot study.**
3 Andrew Houston^{1,2}, Sophie Williams^{1,2}, W 3 Andrew Houston^{4,} Sophie Williams⁴², William Ricketts³, Charles Gutteridge⁴, Chris Tackaberry⁴, John
4 Conibear⁵
-
- 4 Conibear^s
5 ¹ Barts Life
- 5 Barts Life Sciences, Barts Health NHS Trust, London, UK
5 and ² Digital Environment Research Institute, Queen Mary Un
- For Digital Environment Research Institute, Queen Mary University of London, Orientally 2008.
7. ³ Respiratory Medicine, Barts Health NHS Trust, London, UK ³ Respiratory Medicine, Bart
8 ⁴ Clinithink Ltd., London, UK
-
- 8 ^{era} Clinithink Ltd., London, UK
9 ^{– 5} Barts Cancer Centre, Barts 9 Barts Cancer Centre, Barts Health NHS Trust, London, UK

10 Abstract
11 Backgrou 11 **Background:** The digitisation of healthcare records has generated vast amounts of unstructured data,
12 **presenting opportunities for improvement**s in disease diagnosis when clinical coding falls short, such 13 as in the recording of patient symptoms. This study presents an approach using natural language 14 processing to extract clinical concepts from free-text which are used to automatically form diagnostic 15 criteria for lung cancer from unstructured secondary-care data.

16 Methods: Patients aged 40 and above who underwent a chest x-ray (CXR) between 2016-2022 were 17 included. ICD-10 and unstructured data were pulled from their electronic health records (EHRs) over 18 the preceding 12 months to the CXR. The unstructured data were processed using named entity 19 recognition to extract symptoms, which were mapped to SNOMED-CT codes. Subsumption of 20 features up the SNOMED-CT hierarchy was used to mitigate against sparse features and a frequency-21 based criteria, combined with univariate logarithmic probabilities, was applied to select candidate 22 features to take forward to the model development phase. A genetic algorithm was employed to 23 identify the most discriminating features to form the diagnostic criteria.

24 Results: 75002 patients were included, with 1012 lung cancer diagnoses made within 12 months of 25 the CXR. The best-performing model achieved an AUROC of 0.72. Results showed that an existing 26 the Catas of the lung', such as pneumonia, and a 'cough' increased the probability of a lung cancer 27 diagnosis. 'Anomalies of great vessel', 'disorder of the retroperitoneal compartment' and 'context-28 dependent findings', such as pain, statistically reduced the risk of lung cancer, making other 29 diagnoses more likely. The performance of the developed model was compared to the existing 30 cancer risk scores, demonstrating superior performance.

31 Conclusions: The proposed methods demonstrated success in leveraging unstructured secondary-32 care data to derive diagnostic criteria for lung cancer, outperforming existing risk tools. These 33 advancements show potential for enhancing patient care and results. However, it is essential to 34 tackle specific limitations by integrating primary care data to ensure a more thorough and unbiased 34 tacks specific limitations by integrating primary care data to ensure a more thorough and unbiased 2

- 35 development of diagnostic criteria. Moreover, the study highlights the importance of contextualising
36 SNOMED-CT concepts into meaningful terminology that resonates with clinicians, facilitating a
-
- 37 clearer and more tangible understanding of the criteria applied.
- 38 Keywords: Electronic Health Records; Natural Language Processing; Cancer; Diagnostics; SNOMED-
- 39 CT; Machine Learning; Genetic Optimisation $\frac{3}{2}$ C₁, Machine Learning; Genetic Optimisation

Background
41 Lung cancer stands as one of the most common and serious types of cancer, ranking 2nd in terms of 42 new cases and 1^{st} in terms of mortalities, according to global statistics from 2020 [1]. The most 43 recent statistics show that, in England, only 29.4% of lung cancer cases are identified at stages 1 and 44 2 [2], underscoring the critical need for improved diagnostic criteria and detection methods to 45 enhance the chances of successful treatment and reduce the burden of this disease on patients and 46 healthcare systems. Recognising this urgency, the NHS has a long-term plan to diagnose 75% of all 47 lung cancers at stages 1 and 2 by 2028, aiming to significantly improve early detection rates and 147 lung cancers at stages 2 and 2 by 2029, aiming to significantly improve early detection rates and patient outcomes. 48 patient outcomes.
49 Early diagnosis is imperative given the aggressive nature of lung cancer, with delays in detection

50 resulting in patients presenting with more advanced stages of the disease. Recent data published by 51 the Office for National Statistics and Public Health England showed the 5-year survival rate among 52 patients diagnosed with stage 1 lung cancer was 56.6%, with this figure reducing to only 2.9% among 53 those diagnosed with stage 4 disease [3]. Additionally, precise diagnostic criteria play a pivotal role in 54 distinguishing lung cancer from a spectrum of cardiothoracic and respiratory conditions that may 55 exhibit similar symptoms. With that said, to ensure the cost-effectiveness and cost-benefit of 56 targeted interventions aimed at improving the diagnosis of lung cancer, judicious allocation of 56 targeted interventions aimed at improving the diagnosis of lung cancer, judicious allocation of 57 Fresources is required [4].
58 Felectronic health records (EHRs) have revolutionized clinical research by offering a vast and

59 comprehensive repository of patient information. Records encompass a range of data, including 60 patient demographics, medical history, laboratory results, medication prescriptions, and procedure 61 information. Such extensive and structured data enable researchers to conduct large-scale, 62 population-based studies, aiding in the identification of trends $[5]$, risk factors $[6-8]$, and treatment 63 outcomes [9,10]. However, a significant limitation of EHRs pertains to accuracy and completeness, 64 particularly among symptoms and diagnosis data. Symptoms and diagnoses are often documented in 64 particularly among symptoms and diagnosis data. Symptoms and diagnoses are often documented in

65 65 unstructured free-text clinical notes, requiring manual coding into clinical ontologies such as ICD-10
66 and SNOMED-CT. The process of clinical coding can introduce inaccuracies and 'missingness' in the 67 data, posing considerable challenges for clinical research [11,12]. Considering these challenges, 68 techniques such as natural language processing (NLP) offer valuable solutions for not only mitigating 69 the limitations of structured data but also unlocking valuable insights that may be exclusive to free-70 text narratives of patient encounters.

71 Natural Language Processing (NLP) has gained utility in extracting and analysing information in 72 Electronic Health Records (EHRs). Koleck et al. (2019) conducted a literature review, finding 27 73 relevant studies using NLP to analyse symptoms in EHR narratives [13]. NLP has been used for 74 auditing discharge reports $[14]$, predicting readmissions $[15]$, and aiding in diagnosis $[16-18]$. 75 Weissman et al. (2016) used NLP to classify discharge documents based on critical illness-related 76 keywords with high accuracy [14]. Greenwald et al. (2017) developed an NLP tool to extract 77 readmission-related concepts and achieved comparable performance to existing prediction models 78 [15]. In oncology, NLP extracted features from CT reports for predicting lymph node metastasis in 79 non-small cell lung cancer (NSCLC) with competitive performance [16]. Despite its potential, there's a 80 gap in applying NLP to oncology symptoms, highlighting an opportunity for further research [13].

81 While NLP has demonstrated its effectiveness in various healthcare applications, there is a growing 82 recognition of the advantages of extracting ontological concepts rather than use-case-specific 83 concepts [19,20]. This approach provides a more generalised framework for understanding and 84 organising medical information, contributing to interoperability [21,22] and facilitating the linkage 85 with already coded, structured, clinical data found in the EHR. This transition to ontological concept 86 extraction aligns with the broader adoption of standardised medical terminologies like SNOMED CT, 87 which play an important role in structuring and organizing clinical data for improved healthcare $\begin{array}{ccc} \text{88} & \text{decision-making and research.} \end{array}$ 88 decision-making and research.

89 89 From a machine learning perspective, extraction of concepts from a hierarchical ontology offers a
90 crucial advantage, enabling the retention of valuable information, even when a patient reports rarer 91 or more specific symptoms. For instance, when a patient mentions a symptom like a 'chesty cough', 92 machine learning systems can link it to a higher-level concept in the ontology, such as "cough." This 93 hierarchical relationship allows the model to preserve the broader context and meaning of the 94 symptom, preventing the loss of nuanced information that might occur in non-hierarchical concept 95 lists, where rare features might otherwise be removed. Failure to account for such sparsity could 96 result in poor or unreliable classification performance [23,24].

97 Given the promise of NLP for the accurate extraction of relevant features, at scale, this study applies 98 NLP to extract SNOMED-CT concepts from free-text notes, applies subsumption to elevate rarer 99 symptoms up the ontological hierarchy, then feeds the final feature set into a machine learning 100 framework to train a model to discriminate lung cancer from other diseases. Furthermore, this study 101 provides an exploration into how feature weights might be affected by demographic information like 102 age, sex and ethnicity.
102 age, sex and ethnicity.

102 $\frac{1}{2}$ 103
104

104 Methodology
105 Fligibility

105 Englishing
106 Data War

106 Data were extracted from the Barts Health NHS Trust Data Warehouse for all patients meeting the
107 following eligibility criteria: Patients referred for a chest x-ray (CXR), aged 40 years or older at the 108 point of referral, during two time periods between 01 Jan 2016 and 31 Dec 2019 or 01 Jan 2022 and 109 31 Dec 2022 were eligible for inclusion. The time window of 01 Jan 2020 - 31 Dec 2021 were not 110 considered due to deviations from the typical cancer care-pathways as a result of the COVID-19 111 pandemic. Patients who had opted out of their data being used for research, those without medical 112 notes beyond four years from the original x-ray, unless a second confirmatory x-ray within four years 112 notes beyond four years from the original x-ray, unless a second confirmation \mathcal{L}^2

113 ruled out lung cancer, and patients with an existing or historical diagnosis of any cancer were
114 excluded from participation in the study. 113

 115 Data Sources

115 Data Sources
116 All free-text data contained in the secondary care EHR system, from one year prior to the date of the 117 first chest X-ray, were extracted and combined with demographic information, including Age, Sex and 118 Ethnicity, and ICD-10 data from the same time period. Additionally, diagnostic data in the form of 119 ICD-10 codes and the Somerset Cancer Registry were extracted for the subsequent four years post-120 CXR, or up to the maximum available timepoint.

121 To determine the ground truth, a patient was labelled as having lung cancer if a diagnosis was 122 recorded in the Somerset Cancer Registry, or an ICD-10 code of C34 (Malignant neoplasm of 123 bronchus and lung) was present in the patient's EHR post-CXR. Considering the potential delays in 124 diagnoses, post-CXR, and the delays in uploading this information onto the electronic health records 125 system, model training was performed iteratively, each time re-labelling the ground truth to consider 126 an additional month of diagnoses. The iterative process was performed first considering only 127 patients diagnosed with lung cancer within the subsequent month following their CXR, continuing to 128 add more patients until 12-months post-CXR. Instances of lung cancer diagnoses over time the 129 respective model performance is presented in Fig. 1a.

129 respective model performance is presented in Fig. 1a.

130 Feature Extraction
131 To extract structured information from the free-text data, named entity recognition (NER) was 132 performed using the NLP software, CLIX (Clinithink Ltd., London, UK). The free-text was queried 133 against two resource sets, a 'Core-Problems' list containing common clinical symptoms and 134 diagnoses, and the Human Phenotype Ontology. The top 100 clinical features for each resource set 135 are presented in the supplementary file.

136 Feature Engineering

137 To handle missing data, sex and ethnicity were imputed using the most common category. Symptom 138 data were binary, and an assumption was made that if a diagnosis or symptom was not found in $\frac{1}{3}$ 88 data were binary, and an assumption was made that if a diagnosis or symptom was not found in $\frac{1}{3}$

139 140 either the structure in the structure in the NLP algorithm, the patient did not have the p

140 diagnosis or symptom. 142 the sparseness of features in the lower levels of the SNOMED-CT hierarchy, we employed a 143 subsumption process to generate and maintain features at higher levels of the hierarchy, ensuring 144 the inclusion of all subordinate features.

145 Feature Selection

146 Given the high dimensionality, with the number of symptom features exceeding 12,000, the dataset 147 could not be analysed statistically. Instead, a genetic approach was taken. First, symptom features 148 were removed where less than 0.5% of all patients or less than 5% of lung cancer patients had the 149 symptom documented in their notes. Thereafter, the remaining features were ranked according to 150 their Bayesian importance value, calculated as:

$$
IMPTNB = |log(p(x_i = 1|y_j = 1)) - log(p(x_i = 1|y_j = 0))|
$$

151 where xi and yj are 1-dimensional binary arrays indicating the presence of feature *t* and diagnosis *j*
152 for each patient. 152 for each patient.
153 Following the ranking of all features, starting from the lowest ranking symptom, symptoms were

154 Followed should they have a Jaccard coefficient greater than 0.8. Thereafter, the remaining 155 symptoms were input into a tabu asexual genetic algorithm (TAGA) [25], configured to select the 156 feature set which maximises the area under the receiver operating characteristic curve (AUROC). 157 TAGA was tasked with returning λ features, where λ is a number between 5 and 20. The rationale for 158 capping the number of features included in a model at 20 was to ensure the interpretability of the 159 capping the number of features included in a model at 20 was to ensure the interpretability of th 159 final diagnostic criteria and to prevent overfitting.
160 Madel Development and Evaluation

160 Model Development and Evaluation

161 161 20% of the data was held out of the model development process and used as a test set, with the
162 – remaining 80% being used for training and validation. For each model, a 5-fold cross-validation 163 process was applied to select the most relevant features and identify the appropriate 164 by perparameters for the model, following which performance was examined using the test set. The 165 performance of the trained models was assessed using the following diagnostic test characteristics; 166 accuracy, sensitivity, and specificity, in addition to the calculation of the AUROC, with AUROC acting 167 as the primary evaluation measure. 167 as the primary evaluation measure.
168 – This study considered the following classification models: Logistic Regression, Mixed Naïve Bayes,

169 and Decision Trees. The rationale for the selection of these models lies in their interpretability and 170 and Decision Decision Trees. The rationale for the selection of the selection o 170 ease of application.
171 Comparison with existing risk tools

172 To determine whether the proposed method improves the diagnosis of lung cancer beyond that of 173 existing methods that make use of similar features, a comparison with existing risk tools was 174 performed. The proposed method was compared against the lung cancer component of the QCancer 175 score [26,27] and the lung cancer-related risk assessment tools listed on the Cancer Research UK 176 website [28] and the lung cancer-related risk assessment to $\frac{1}{2}$ and $\frac{1}{2}$ and

176 website [28]. 178 the same test set used for all previous comparisons. The risk assessment tools (RATs) of Hamilton et 179 al. (2005) [28] are solely a set of feature combinations and their associated positive predictive values. 180 Therefore, to apply the RATs to the data used in this body of work, a logistic regression model was 181 trained for each feature combination, using the training set used for all previous experiments, 182 returning the probability of lung cancer for each patient in the test set. Thereafter, the highest 183 probability of all feature combinations was regarded as the final prediction for each patient. As 184 before, the AUROC was used to compare each model. 184 before, the AUROC was used to compare each model.

185

185

186 Results
187 Demogr

187 Demographic Information
188 — In total, 75002 patients (35628 female) were included in this study. The study population had a mean

189 age of 63 years ± 14 years. 36123 identified as 'White', 20219 identified as 'Asian', 7851 identified as

190 Glack', 3330 identified as 'Other' and 835 identified as 'Mixed Ethnicity'. Two and 6644 patients were

191 missing sex and ethnicity data, respectively, which were imputed.

192 In total, over the 12-month observation period after the first CXR, a total of 1012 lung cancer 193 diagnoses were made. The occurrence of lung cancer at each monthly increment are shown in Fig. 194 1a. Also, plotted are the number of diagnoses made following a repeat scan. The total number of 195 diagnoses following the first scan plateaued four months post-CXR, with additional diagnoses after 196 which time being made only after a further CXR. Aside from lung cancer, other common respiratory 197 diagnoses in the dataset included: COPD (n=1883), atelectasis (n=2432) and pneumonia (n=398).

197 diagnoses in the dataset in the dataset in the dataset included: COPD (n=398) and pneumonia (n=398). And p
1983 and prick Score Performance Characteristics

Risk-Score Performance Characteristics
199 Fig. 1b shows the performance of each of the three models, in terms of AUROC, across all 12 time 200 intervals. The performance of the logistic regression model significantly outperformed the other two 201 models, in terms of absolute performance but also model stability, denoted by the reduced standard 202 deviation of AUROC. Of note, the performance of all models was less stable in the first five months, 203 highlighting the likelihood of poorer class labelling resulting from a delay in diagnoses being 204 uploaded to the EHRs. Considering the stabilisation in performance at five months, coupled with the 205 plateau in diagnoses without additional scans, to strike the balance between the highest quality 206 labelling and stable model performance, the ground truth labels established at 5-months were used end the ground term of ground terms in the ground term in the ground term is the ground term in the ground ter
207 for the ground all the stabilished at 5-months were used at 5-months were used at 5-months were used at 5-

207 for all future experiments.

Figure 1: a) The number of diagnoses occurring at each monthly interval, for the subsequent 12 months post-CXR. b) The mean AUROC of the three tested models across each monthly interval, demonstrating the performance stabilisation and plateau from month five onwards. The shaded area

Influence of Age, Sex and Ethnicity on Risk-Score Performance

210 Table 1 shows the performance of the model solely using the symptoms found in the EHR of the

211 patient, then with the inclusion of demographic data. The 211 patient, then with the inclusion of demographic data. The inclusion of age and ethnicity was shown
212 to improve the diagnostic performance of the model, increasing AUROC to 0.69 and 0.67,
213 respectively. Gender did 212 to improve the diagnostic performance of the model, increasing AUROC to 0.69 and 0.67,
213 respectively. Gender did not improve model performance in isolation. The inclusion of age, gender
214 and ethnicity improved mo 213 respectively. Gender did not improve model performance in isolation. The inclusion of age, gender
214 and ethnicity improved model performance across all metrics resulting in an AUROC of 0.72, with an
215 associated se 214 and ethnicity improved model performance across all metrics resulting in an AUROC of 0.72, with an
215 associated sensitivity and specificity of 0.69 and 0.67, respectively.
215 Table 1: Performance characteristics of

215 associated sensitivity and specificity of 0.69 and 0.67, respectively.
215 associated sensitivity and specificity of 0.69 and 0.67, respectively.
215 Table 1: Performance characteristics of the logistic regression mode 215 associated sensitivity and specificity of the logistic regression
215 associated sensitivity of the demographic features is incorporated. Values
22 standard deviation of the cross-validation performed on the training The 1: Performance combination of the demographic features is incorporated. Values in brackets indicate the mean and

standard deviation of the cross-validation performed on the training set.

Input Features Accuracy Accur

217 Feature *Importance*
218 To understand how
219 Explanations) value:
220 Individuals exhibitin To understand how each predictor influences the prediction of lung cancer, SHAP (Shapley Additive
219 Explanations) values were calculated (Fig. 2). The most influential feature was age, with older
220 individuals exhibiti 220 individuals exhibiting a significant increase in the model's output towards predicting lung cancer.
221 Additionally, the presence of an 'existing disorder of the lung' was found to positively impact the prediction. No individuals exhibiting a significant increase in the model's output towards predicting lung cancer.
221 Additionally, the presence of an 'existing disorder of the lung' was found to positively impact the
222 prediction. No 222 prediction. Notably, individuals of white ethnicity had the greatest influence on the model outputs,
223 increasing the SHAP value towards the prediction of lung cancer, although all ethnicities displayed
224 varying d 223 increasing the SHAP value towards the prediction of lung cancer, although all ethnicities displayed
224 varying degrees of impact toward a positive diagnosis. Males had an increased SHAP value,
225 contributing to the 224 varying degrees of impact toward a positive diagnosis. Males had an increased SHAP value,
225 contributing to the prediction. Conversely, the presence of a 'congenital anomaly of a great vessel'
226 and 'disorders of t 225 contributing to the prediction. Conversely, the presence of a 'congenital anomaly of a great vessel'
226 and 'disorders of the retroperitoneal compartment' reduced the SHAP value. Context-dependent
227 factors, such as 226 and 'disorders of the retroperitoneal compartment' reduced the SHAP value. Context-dependent
227 factors, such as pain, bleeding, and arthropathy, also reduced the SHAP value, making a prediction of
228 lung cancer les 227 factors, such as pain, bleeding, and arthropathy, also reduced the SHAP value, making a prediction of
228 lung cancer less likely. Finally, the presence of a cough was found to increase the SHAP value, further
229 emph 228 Iung cancer less likely. Finally, the presence of a cough was found to increase the SHAP value, further
229 Iung cancer less likely. Finally, the prediction of lung cancer.
230 Iung a prediction of lung cancer.
230 Iun

229 emphasising its relevance in the prediction of lung cancer.
230 Given the high-level nature of several the features, due to the subsumption process applied, an
231 exploration into what symptoms or co-morbidities compr 230 Given the high-level nature of several the features, due
231 exploration into what symptoms or co-morbidities comp
232 shows each of the selected features, and some of the 231 exploration into what symptoms or co-morbidities comprised such features was performed. Fig. 3
232 shows each of the selected features, and some of the most prominent features which comprise
233 them. 232 shows each of the selected features, and some of the most prominent features which comprise
233 them.
234 *Comparison of the proposed approach with other cancer risk tools* 233 shows each of the selected features, and some of the most prominent features which comparison of the proposed approach with other cancer risk tools

234 Compo
234 Compo
235 Fig. 4 234 Comparison by the proposed approach with other cancer risk tools
235 Fig. 4 shows the receiver operating characteristic curve of the m
236 described in this paper, the QCancer score [26,27], and the lung cancer
237 lis 236 described in this paper, the QCancer score [26,27], and the lung cancer related risk assessment tools
237 listed on the Cancer Research UK website [28]. As previously reported, the proposed methods
238 resulted in an A 237 listed on the Cancer Research UK website [28]. As previously reported, the proposed methods
238 resulted in an AUROC of 0.72. The application of the QCancer calculator to the test set used
239 throughout this paper res resulted in an AUROC of 0.72. The application of the QCancer calculator to the test set used
239 throughout this paper resulted in an AUROC of 0.67 and the methods of Hamilton et al. (2005)
240 achieved and AUROC of 0.55. 239 throughout this paper resulted in an AUROC of 0.67 and the methods of Hamilton et al. (2005)
240 achieved and AUROC of 0.55. 240 achieved and AUROC of 0.55.

Figure 2: A summary plot of the SHAP values denoting the impact of each feature in the best performing model, on the prediction of lung cancer. Shading of each datapoint indicates the value of the feature. For all binary f of the feature. For all binary features, except age, a red value denotes a "true" value and blue denotes a false value. For age, the bluer a datapoint reflect a younger age, and the redder a data denotes a false value of age, the blue reflect a datapoint reflect a younger age, and the redder the patient. point, the older the patient.

Figure 3: Visualisation of common concepts subsumed into higher level concepts in the SNOMED-CT hierarchy.

It is made available under a CC-BY 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.02.20.24303084;](https://doi.org/10.1101/2024.02.20.24303084) this version posted February 21, 2024. The copyright holder for this preprint

 $\frac{1}{2}$ of Hamilton et al. (2005), when applied to the test set used in this study.
Discussion of Hamilton et al. (2005), when applied to the test set used in this study.
Discussion
This work aimed to explore the use of NLP for the extraction of SNOMED-CT concepts from

241
242
243
244 242 Biseassion
243 This work
244 unstructure
245 posed by sp 244 unstructured clinical free-text, coupled with subsumption techniques to address the challenges
245 posed by sparse features in high-dimensional datasets. Leveraging genetic optimisation and machine
246 learning, the ge 245 posed by sparse features in high-dimensional datasets. Leveraging genetic optimisation and machine
246 learning, the generated dataset was used to develop a predictive model for lung cancer diagnosis.
247 Model develop 246 bearning, the generated dataset was used to develop a predictive model for lung cancer diagnosis.
247 Model development resulted in a classifier with stable performance characterised by low standard deviations between 247 Model development resulted in a classifier with stable performance characterised by low standard
248 deviations between the cross-validation folds and an AUROC of 0.72. Additionally, the model offers a
249 balanced tra deviations between the cross-validation folds and an AUROC of 0.72. Additionally, the model offers a
249 balanced trade-off between sensitivity and specificity with values of 0.69 and 0.66, respectively.
250 Notably, our p 249 balanced trade-off between sensitivity and specificity with values of 0.69 and 0.66, respectively.
250 Notably, our proposed methodology outperforms both the QCancer calculator [26,27] and the
251 methods introduced by 249 balanced trade-off between sensitivity and specificity with values of 0.09 and 0.00, respectively.
250 Notably, our proposed methodology outperforms both the QCancer calculator [26,27] and the
251 methods introduced by 251 methods introduced by Hamilton et al. (2005) [28], highlighting the promise NLP and machine
16 2533 methods introduced by Hamilton et al. (2005) 28 , highlighting the promise NLP and mathematical mathematical mathematical mathematical mathematical mathematical mathematical mathematical mathematical mathematical

252

predictive models in the field of lung cancer risk assessment.
254 The incorporation of subsumption techniques helped mitigate the challenges posed by sparse
255 Features within our predictive model. By hierarchically orga 254 The incorporation of subsumption techniques helped mit
255 features within our predictive model. By hierarchically o
256 concepts, subsumption allowed us to identify broader, hig 255 Features within our predictive model. By hierarchically organising and abstracting SNOMED-CT
256 concepts, subsumption allowed us to identify broader, higher-level categories that encapsulate a
257 range of related cli 256 concepts, subsumption allowed us to identify broader, higher-level categories that encapsulate a
257 range of related clinical terms. This not only alleviated the risk of overfitting and unreliable
258 performance, a c 257 range of related clinical terms. This not only alleviated the risk of overfitting and unreliable
258 performance, a common concern in models trained on sparse data [23,24], but enhanced the
259 generalisability of our 258 performance, a common concern in models trained on sparse data [23,24], but enhanced the generalisability of our model. However, the introduction of more abstract, top-level features meant that the final model was root 259 generalisability of our model. However, the introduction of more abstract, top-level features meant
260 that the final model was rooted in a level of granularity less commonly used in routine clinical
261 practice. Thi 260 that the final model was rooted in a level of granularity less commonly used in routine clinical
261 practice. This has important implications for the practical translation and messaging of the model,
262 highlighting 261 practice. This has important implications for the practical translation and messaging of the model,
262 highlighting the need for a clear and effective strategy to bridge the gap between the model's
263 output, which o 262 highlighting the need for a clear and effective strategy to bridge the gap between the model's
263 output, which operates at a higher conceptual level, and the clinical realities on the ground, which
264 makes use of s highlighting the need for a clear and effective strategy to bridge the gap between the model's
263 output, which operates at a higher conceptual level, and the clinical realities on the ground, which
264 makes use of speci

264 makes use of specific and well-established terminology.
265 The primary function of our model is to evaluate the likelihood of a positive lung cancer diagnosis
266 when a patient enters the clinical pathway for this pu 265 The primary function of our model is to evaluate the l
266 when a patient enters the clinical pathway for this purpo
267 early diagnosis and intervention, the success of a diagr 266 The primary function of our model is to entimate the linearce of a position of primary single is
266 The primary function of the linical pathway for this purpose. While this is a valuable step in enhancing
267 The earl 267 early diagnosis and intervention, the success of a diagnostic tool is often measured by its ability to
268 identify patients even before they enter the diagnostic pathway [29], ultimately achieving a
269 significant st 268 identify patients even before they enter the diagnostic pathway [29], ultimately achieving a
269 significant stage shift in the diagnostic process which is associated with improved mortality rates
270 [30]. The primary 269 significant stage shift in the diagnostic process which is associated with improved mortality rates
270 [30]. The primary limitation of this study is its reliance on secondary care data, which did not provide
271 suffi 270 [30]. The primary limitation of this study is its reliance on secondary care data, which did not provide
271 sufficient longitudinal information to facilitate such an analysis. It is essential to recognise that most
27 271 sufficient longitudinal information to facilitate such an analysis. It is essential to recognise that most
272 patient interactions with the healthcare system before a lung cancer diagnosis occur in primary care
273 fa 272 patient interactions with the healthcare system before a lung cancer diagnosis occur in primary care
273 facilities, where symptoms are first reported and initial evaluations are made [31–34]. The absence
274 of primar 273 facilities, where symptoms are first reported and initial evaluations are made [31–34]. The absence
274 of primary care data in our study thus limits the real-world applicability of the developed methods
275 and highli 274 of primary care data in our study thus limits the real-world applicability of the developed methods
275 and highlights the need for future efforts to incorporate primary care data to truly impact early
276 detection an 275 and highlights the need for future efforts to incorporate primary care data to truly impact early
276 detection and diagnosis in clinical practice. 276 detection and diagnosis in clinical practice. 276 detection and diagnosis in clinical practice.

277 employed to derive the features predictive of lung cancer, most patients had only one document
279 before their CXR, a referral letter. Therefore, we must consider the possibility that the referring
280 clinician may only 279 before their CXR, a referral letter. Therefore, we must consider the possibility that the referring
280 clinician may only include symptoms that they perceive to be relevant to the suspected diagnosis for
281 which the 280 clinician may only include symptoms that they perceive to be relevant to the suspected diagnosis for
281 which the scan is required, omitting other symptoms which may prove predictive. Such a limitation
282 will often 281 colinication may only include symptoms that they perceive to be relevant to the supplement magnetic relevant
282 colinical often be present in such predictive modelling studies. However, if each patient were to have
28 will often be present in such predictive modelling studies. However, if each patient were to have
283 more clinical notes before the suspecting of lung cancer the effect of such bias may be reduced.
284 Clinically, the abs

more clinical notes before the suspecting of lung cancer the effect of such bias may be reduced.
284 Clinically, the absence of staging data restricts our insight into the model's capacity to identify lung
285 cancer at an 284 Clinically, the absence of staging data restricts our insight into the model's capacity to identify
285 cancer at an early stage, which is crucial for understanding the impact of the predictions on pa
286 outcomes. Add 284 Clinically, the absence of staging data restricts our insight into the model's capacity to identify lung
285 cancer at an early stage, which is crucial for understanding the impact of the predictions on patient
286 out 286 outcomes. Additionally, the NER methods employed were not trained to extract genetic variants
287 from pathology reports, specifically lung-cancer specific risk loci, which could further improve the
288 performance of 286 outcomes. Additionally, the NER methods employed were not trained to extract genetic variants
287 from pathology reports, specifically lung-cancer specific risk loci, which could further improve the
288 performance of 288 performance of the model [35]. Future studies with access to more comprehensive and longitudinal
289 patient data, including primary care information, genomic data and staging details, could help
290 address these limi 289 patient data, including primary care information, genomic data and staging details, could help
290 address these limitations and further enhance the efficacy and generalisability of the developed
291 predictive model. 290 address these limitations and further enhance the efficacy and generalisability of the developed
291 predictive model.
292 **Conclusions** 291 predictive model.
292 Conclusions
292 Conclusions

292 **Conclusions**
293 This research hig 292 Conclusions
293 This researc
294 learning tecl
295 data. The s 294 Iearning techniques to enhance diagnostic criteria for lung cancer using unstructured healthcare
295 data. The study's key findings include the successful identification of discriminating features
296 associated with l 295 data. The study's key findings include the successful identification of discriminating features
296 associated with lung cancer diagnosis and achieving promising AUROC scores which outperform
297 other comparable risk 295 data. The study's key findings include the successful identification of discriminating features
296 associated with lung cancer diagnosis and achieving promising AUROC scores which outperform
297 other comparable risk 297 by the comparable risk assessment tools. Such advancements hold promise for improving patient care
298 and outcomes, albeit with a need to address certain limitations through the incorporation of primary
299 care data 298 and outcomes, albeit with a need to address certain limitations through the incorporation of primary
299 care data for more comprehensive and unbiased criteria development.
300 299 care data for more comprehensive and unbiased criteria development.
300 2999 care data for more comprehensive and unbiased criteria development. The comprehensive and unbiased criteria development. The comprehensive and unbiased criteria development. The comprehensive and unbiased criteria

- Solingthalties

202 AUROC Area Under the Receiver Operating Characteristic curve

203 COPD Chronic Obstructive Pulmonary Disease

204 CT Computed Tomography
- 303 COPD Chronic Obstructive Pulmonary Disease
304 CT Computed Tomography
305 CXR Chest X-ray
-
-
- 304 CT Computed Tomography
305 CXR Chest X-ray
306 EHR Electronic Health Record 305 CXR - Chest X-ray
306 EHR - Electronic Health Reco
307 ICD-10 - International Classif 305 CXR - Chest X-ray
- 306 EHR Electronic Health Record
307 ICD-10 International Classification of Diseases
308 NER Named Entity Recognition
309 NHS National Health Service
-
-
- 308 NER Named Entity Recognition
309 NHS National Health Service
310 NLP Natural Language Processing 310 NLP - Natural Language Processing
311 NSCLC - Non-Small Cell Lung Cancer 310 MLP - Natural Language Proces
311 MSCLC - Non-Small Cell Lung C
312 SHAP - Shapley Additive Explar
- 311 NSCLC Non-Small Cell Lung Cancer
312 SHAP Shapley Additive Explanatio
313 SNOMED-CT Systematized Nomer
- 312 SHAP Shapley Additive Explanation
313 SNOMED-CT Systematized Nomenc
314 TAGA Tabu Asexual Genetic Algoritl
- SHAP Shapley Additive Explanations
313 SNOMED-CT Systematized Nomenclature of Medicine Clinical Terms
314 TAGA Tabu Asexual Genetic Algorithm
- 314 TAGA Tabu Asexual Genetic Algorithm 314 TAGA - Tabu Asexual Genetic Algorithm

315 Beelatations
316 Ethics Approv
317 This study was
318 granted by the
320 by the NHS (317 This study was submitted to an NHS Rese
318 granted by the NHS Health Research Aut
319 consent to participate was waived by the P
320 by the NHS Confidentiality Advisory Grou
321 2006. The study also adhered to the NHS 317 This study was submitted to an NHS Research Ethics Committee, with subsequent approval being
318 granted by the NHS Health Research Authority (IRAS ID: 320934). The requirement for informed
319 consent to participate w 319 consent to participate was waived by the NHS Health Research Authority following support, granted
320 by the NHS Confidentiality Advisory Group, under Section 251 of the National Health Service Act
321 2006. The study 320 by the NHS Confidentiality Advisory Group, under Section 251 of the National Health Service Act
321 2006. The study also adhered to the NHS National Data Opt-Out to respect patients' decision to opt
322 out of the use 321 2006. The study also adhered to the NHS National Data Opt-Out to respect patients' decision to opt
322 out of the use of their data for research purposes.
323 Consent for Publication 321 2006. The study also adhered to the NHS National Data Opt-Out to respect patients' decision to opt
322 out of the use of their data for research purposes.
323 Consent for Publication
325 Not applicable

-
-
- 323
323 *Consent for Publication*
325 Not applicable
325
- 324
325
326
327

324 Consent for Pablication
325 Not applicable
326 Availability of data and
328 The datasets consented

326
327 Availability of a
328 The datasets g
329 due their iden 328
329
330
331 328 The datasets generated during and the datasets generated during and due their identifiable, sensitive, authors upon reasonable reque Governance Team and with approximate Group. 329 due their identifiable, sensitive, and confidential nature. Data are however available from the
330 authors upon reasonable request and with permission of Barts Health NHS Trust Information
331 Governance Team and with 330 authors upon reasonable request and with permission of Barts Health NHS Trust Information
331 Governance Team and with appropriate approvals in place from the NHS Confidentiality Advisory
332 Group.
333 Competing Inter 331 Governance Team and with appropriate approvals in place from the NHS Confidentiality Advisory
332 Group.
333 Competing Interests

332 Group.
333
334 *Competing Interests*
335 CT is the CEO of Clinithink Ltd., the entity that owns the NLP software employed for extracting clinical
336 features from the free-text in this study. The remaining authors dec Example
333
334 *Compet*
335 CT is th
336 feature. 337
338 335 CT is the CEO of Clini
335 CT is the CEO of Clini
336 features from the fre
337 interests. 336 features from the free-text in this study. The remaining authors declare that they have no competing
337 interests.
338 Funding 337 interests.
338 *Funding*
340 This work is sponsored by AstraZeneca UK Ltd. The funding body was independent of the study team

337 Interests.
338 Funding
340 This work
341 and was n 340
341
342 339 Funding
 340 This wor
 341 and was
 342 in writing
 343 340 This work is sponsored by AstraZeneca UK Ltd. The funding body was independent of the study team
341 and was not involved in the design of the study or collection, analysis, and interpretation of data or
342 in writing

345 AH: Data curation, Software, Validation, Formal analysis, Project administration, Visualization, 343
343 Authors' contributions
345 AH: Data curation, Softv
346 Writing – original draft; SV 346
347
348 344 Authors' contributions
345 **AH**: Data curation, S
346 Writing – original draft
347 **WR**: Writing – origin
348 Resources; JC: Superv
349 Investigation, Writing – 345 AH: Data curation, Software, Validation, Tormal analysis, Troject administration, Visualization,
346 Writing – original draft; SW: Supervision, Project administration, Writing – original draft, Resources;
347 WR: Writi 347 WR: Writing – original draft; SW: Supervision, Project administration, Writing – original draft; CG: Resources; CT: Funding acquisition, Project administration, Resources; JC: Supervision, Project administration; All a 348 Resources; JC: Supervision, Project administration; All authors: Conceptualisation, Methodology,
349 Investigation, Writing – review & editing
350 1348 Resources; J.C. Supervision, Project administration; All authors: Conceptualisation, Methodology,
349 Investigation, Writing – review & editing
350 350
 350

- 351 Acknowledgement
352 We wish to acknowledge the technical support team at Clinithink Ltd. for their assistance in
353 developing the NLP methods employed in this study.
- 353 developing the NLP methods employed in this study.
 $\frac{1}{100}$ 353 developing the NLP methods employed in this study.

 $\frac{4}{3}$

-
-
- 444 Ewing M, Naredi F, Nemes 3, et al. Increased consultation frequency in primary care, a risk
marker for cancer: a case-control study. Scand J Prim Health Care. 2016;34:204–11.
445 35 Timofeeva MN, Hung RJ, Rafnar T, et
- marker for cancer: a case-control study. Scand J Prim Health Care. 2010, 34:204–11.
445 35 Timofeeva MN, Hung RJ, Rafnar T, *et al.* Influence of common genetic variation on lu
446 cancer risk: meta-analysis of 14 900 case 445 35 Timofeeva MN, Hung RJ, Rafnar T, *et al.* Influence of common genetic variation on lung

446 cancer risk: meta-analysis of 14 900 cases and 29 485 controls. *Human molecular*

447 genetics, 2012;21:4980-4995.

448 446 cancer risk: meta-analysis of 14 900 cases and 29 485 controls. *Human molecular*
447 genetics, 2012;2*1*:4980-4995.
448
- 447 *genetics*, 2012;*21*:4980-4995.